王丹 谷晓岚 田雨



[摘要]目的 探討达格列净联合利拉鲁肽治疗2型糖尿病的效果。方法 选择2017年1月~2018年10月本院收治的80例2型糖尿病患者为研究对象,按照随机数字表法分为观察组(40例)与对照组(40例)。对照组使用利拉鲁肽,观察组在对照组的基础上早餐前口服达格列净。比较两组干预前后的血糖代谢指标[空腹血糖、餐后2 h血糖、糖化血红蛋白(HbA1c)及胰岛素抵抗指数稳态模型(HOMA-IR)]、血脂代谢指标[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)]、体重指数(BMI),随访1年,统计两组的并发症发生情况。结果 观察组干预后血糖代谢指标中的空腹血糖、餐后2 h血糖、HbA1c及胰岛素抵抗指数(HOMA-IR)水平均低于对照组,差异有统计学意义(P<0.05);观察组干预后血脂代谢指标中的TC、TG、LDL-C水平均低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05)。观察组干预后的BMI低于干预前及对照组干预后,差异有统计学意义(P<0.05)。随访1年期间,观察组的糖尿病足、视网膜病变、周围神经病变及糖尿病肾病发生率均低于对照组,差异有统计学意义(P<0.05)。结论 针对2型糖尿病,在应用利拉鲁肽基础上联合使用达格列净能更好地调节血糖、血脂代谢及机体体质状况,减少或延缓并发症发生。
[关键词]达格列净;利拉鲁肽;2型糖尿病
[中图分类号] R587.1 [文献标识码] A [文章编号] 1674-4721(2020)7(b)-0069-04
Effect of Dapagliflozin combined with Liraglutide in the treatment of type 2 diabetes mellitus
WANG Dan1 GU Xiao-lan1 TIAN Yu2
1. Department of Endocrinology, Dalian Municipal Central Hospital Affilliated to Dalian Medical University, Liaoning Province, Dalian 116033, China; 2. Department of Anesthesiology, Dalian Municipal Central Hospital Affilliated to Dalian Medical University, Liaoning Province, Dalian 116033, China
[Abstract] Objective To investigate the effect of Dapagliflozin combined with Liraglutide in the treatment of type 2 diabetes mellitus. Methods A total of 80 cases with type 2 diabetes mellitus from January 2017 to October 2018 in our hospital were selected as the research objects, and were divided into the observation group (40 cases) and the control group (40 cases) according to the random number table method. The control group was treated with Liraglutide, the observation group was treated with Dapagliflozin before breakfast on the basis of the control group. The blood glucose metabolic indexes (such as abdominal blood glucose, blood glucose 2 hours after meal, HbA1c and HOMA-IR changes), the metabolic indexes of blood lipid (such as total cholesterol [TC], triglyceride [TG], low density lipoprotein [LDL-C] and high density lipoprotein [HDL-C]), the changes of body mass index (BMI) in the two groups before and after intervention were compared. The complications of the two groups were analyzed after one year follow-up. Results The levels of fasting blood glucose, 2-hour postprandial blood glucose, HbA1c and HOMA-IR in the blood glucose metabolic indexes in the observation group after intervention were lower than those in the control group, the differences were statistically significant (P<0.05). The levels of TC, TG and LDL-C in blood lipid metabolic indexes in the observation group after intervention were lower than those in the control group, the levels of HDL-C in the observation group after intervention was higher than control group, the differences were statistically significant (P<0.05). After intervention, the BMI in the observation group was lower than before intervention and in the control group after intervention, the differences were statistically significant (P<0.05). During the follow-up period of one year, the incidence of diabetic foot, retinopathy, peripheral neuropathy and diabetic nephropathy in the observation group were lower than those in the control group, the differences were statistically significant (P<0.05). Conclusion The combination of Liraglutide and Dapagliflozin for type 2 diabetes can better regulate blood sugar, lipid metabolism and body constitution, and reduce or delay the incidence of complications.
[Key words] Dapagliflozin; Liraglutide; Type 2 diabetes mellitus
[作者简介]王丹(1985-),女,汉族,山东长岛人,硕士,主治医师,主要从事内分泌系统常见疾病的临床研究工作
近年来,随着我国人民生产、生活方式的改变以及生活环境的变化,糖尿病发病率呈现显著升高趋势,其中又以2型糖尿病居多[1]。2型糖尿病属于常见的内分泌系统疾病,随着病程的延长存在明显进展趋势,同时体内胰岛素功能逐渐降低,血糖水平出现慢性升高趋势[2]。随着高血糖状态时间的推移,可出现心、脑、肾、眼、外周神经等多脏器功能障碍[3],同时血糖控制不理想还能发生低血糖、糖尿病性酮症酸中毒、高渗性昏迷等急性并发症,故有效地调控患者血糖与代谢水平对维持血糖稳定、延缓甚至避免并发症发生有积极意义[4]。……